Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Kidney Cancer | Research

Changes in disease burden and global inequalities in bladder, kidney and prostate cancers from 1990 to 2019: a comparative analysis based on the global burden of disease study 2019

Authors: Qiao Huang, Jun Yang, Guo-Xiong Liu, Hao Zi, Shi-Di Tang, Hai-Chang Jia, Wei Li, Xiao-Feng Xu, Xian-Tao Zeng

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Bladder, kidney and prostate cancers make significant contributors to cancer burdens. Exploring their cross-country inequalities may inform equitable strategies to meet the 17 sustainable development goals before 2030.

Methods

We analyzed age-standardized disability-adjusted life-years (ASDALY) rates for the three cancers based on Global Burden of Diseases Study 2019. We quantified the inequalities using slope index of inequality (SII, absolute measure) and concentration index (relative measure) associated with national sociodemographic index.

Results

Varied ASDALY rates were observed in the three cancers across 204 regions. The SII decreased from 35.15 (95% confidence interval, CI: 29.34 to 39.17) in 1990 to 15.81 (95% CI: 7.99 to 21.79) in 2019 for bladder cancers, from 78.94 (95% CI: 75.97 to 81.31) in 1990 to 59.79 (95% CI: 55.32 to 63.83) in 2019 for kidney cancer, and from 192.27 (95% CI: 137.00 to 241.05) in 1990 to − 103.99 (95% CI: − 183.82 to 51.75) in 2019 for prostate cancer. Moreover, the concentration index changed from 12.44 (95% CI, 11.86 to 12.74) in 1990 to 15.72 (95% CI, 15.14 to 16.01) in 2019 for bladder cancer, from 33.88 (95% CI: 33.35 to 34.17) in 1990 to 31.13 (95% CI: 30.36 to 31.43) in 2019 for kidney cancer, and from 14.61 (95% CI: 13.89 to 14.84) in 1990 to 5.89 (95% CI: 5.16 to 6.26) in 2019 for prostate cancer. Notably, the males presented higher inequality than females in both bladder and kidney cancer from 1990 to 2019.

Conclusions

Different patterns of inequality were observed in the three cancers, necessitating tailored national cancer control strategies to mitigate disparities. Priority interventions for bladder and kidney cancer should target higher socioeconomic regions, whereas interventions for prostate cancer should prioritize the lowest socioeconomic regions. Additionally, addressing higher inequality in males requires more intensive interventions among males from higher socioeconomic regions.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
3.
Xu Q, Zhang T, Xia T, Jin B, Chen H, Yang X. Epidemiological trends of kidney Cancer along with attributable risk factors in China from 1990 to 2019 and its projections until 2030: an analysis of the global burden of disease study 2019. Clin Epidemiol. 2023;15:421–33.CrossRefPubMedPubMedCentral
4.
Huang Q, Zi H, Luo L, Li X, Zhu C, Zeng X. Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030. BMC Cancer. 2022;22(1):1164.CrossRefPubMedPubMedCentral
5.
Zi H, He S, Leng X, Xu X, Huang Q, Weng H, Zhu C, Li L, Gu J, Li X, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019. Mil Med Res. 2021;8(1):60.PubMedPubMedCentral
6.
Soerjomataram I, Lortet-Tieulent J, Ferlay J, Forman D, Mathers C, Parkin DM, Bray F. Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer. BMC Med Res Methodol. 2012;12:125.CrossRefPubMedPubMedCentral
7.
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al. The global burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRefPubMed
8.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer observatory: Cancer today. Lyon: International Agency for Research on Cancer; 2018. p. 2018.
9.
Fridolin S, Dzintars G, Peter VP, Jan MS. Quantifying changes in global health inequality: the Gini and slope inequality indices applied to the global burden of disease data, 1990-2017. BMJ Glob Health. 2019;4(5):e1500.
10.
Emadi M, Delavari S, Bayati M. Global socioeconomic inequality in the burden of communicable and non-communicable diseases and injuries: an analysis on global burden of disease study 2019. BMC Public Health. 2021;21(1):1771.CrossRefPubMedPubMedCentral
11.
Cao F, He YS, Wang Y, Zha CK, Lu JM, Tao LM, Jiang ZX, Pan HF. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019. Autoimmun Rev. 2023;22(6):103326.CrossRefPubMed
12.
Andrade CAS, Mahrouseh N, Gabrani J, Charalampous P, Cuschieri S, Grad DA, Unim B, Mechili EA, Chen-Xu J, Devleesschauwer B, et al. Inequalities in the burden of non-communicable diseases across European countries: a systematic analysis of the global burden of disease 2019 study. Int J Equity Health. 2023;22(1):140.CrossRefPubMedPubMedCentral
13.
Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021;14(1):197.CrossRefPubMedPubMedCentral
14.
Schlotheuber A, Hosseinpoor AR. Summary measures of health inequality: a review of existing measures and their application. Int J Environ Res Public Health. 2022;19(6).
15.
16.
Global BODC. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 Cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8(3):420–44.CrossRef
17.
Moreno-Betancur M, Latouche A, Menvielle G, Kunst AE, Rey G. Relative index of inequality and slope index of inequality: a structured regression framework for estimation. Epidemiology. 2015;26(4).
18.
Contoyannis P, Hurley J, Walli-Attaei M. When the technical is also normative: a critical assessment of measuring health inequalities using the concentration index-based indices. Popul Health Metrics. 2022;20(1):21.CrossRef
19.
Cumming G. Inference by eye: Reading the overlap of independent confidence intervals. Stat Med. 2009;28(2):205–20.CrossRefPubMed
20.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
21.
Zhang Z, Zhao M, Zhang Y, Feng Y. How does urbanization affect public health? New evidence from 175 countries worldwide. Front Public Health. 2022;10:1096964.CrossRefPubMed
22.
Xiaochen D, Emmanuela G, Alan DL. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. 2022;31(2):129.CrossRef
23.
Jaafarzadeh N, Poormohammadi A, Almasi H, Ghaedrahmat Z, Rahim F, Zahedi A. Arsenic in drinking water and kidney cancer: a systematic review. Rev Environ Health. 2023;38(2):255–63.CrossRefPubMed
24.
Marmot M, Friel S, Bell R, Houweling TA, Taylor S. Closing the gap in a generation: health equity through action on the social determinants of health. Lancet. 2008;372(9650):1661–9.CrossRefPubMed
25.
Jubber I, Ong S, Bukavina L, Black PC, Comp茅rat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, et al. Epidemiology of bladder Cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84(2):176–90.CrossRefPubMed
26.
Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, Fan ZL, Han P, Huang YR, Huang X, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022;9(1):44.PubMedPubMedCentral
27.
Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, Datta S, Hanbury D, Hrouda D, Oades G, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10(5):e35938.CrossRef
28.
Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.CrossRefPubMed
29.
Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473–80.CrossRefPubMedPubMedCentral
30.
Cepeda-Benito A, Doogan NJ, Redner R, Roberts ME, Kurti AN, Villanti AC, Lopez AA, Quisenberry AJ, Stanton CA, Gaalema DE, et al. Trend differences in men and women in rural and urban U.S. settings. Prev Med. 2018;117:69–75.CrossRefPubMedPubMedCentral
31.
Thibaut F, Jhanwar VG. Gender differences: the new challenge for the next years. Indian J Psychiat. 2020;62(2).
32.
Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El GF, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827–39.CrossRefPubMedPubMedCentral
33.
Banks I, Baker P. Men and primary care: improving access and outcomes. Trends Urol Men’s Health. 2013;4(5):39–41.CrossRef
34.
Horstmann M, Witthuhn R, Falk M, Stenzl A. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med. 2008;5(4):385–94.CrossRefPubMed
35.
Lucca I, Klatte T, Fajkovic H, de Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol. 2015;12(10):585–92.CrossRefPubMed
36.
Luzzati T, Parenti A, Rughi T. Economic growth and Cancer incidence. Ecol Econ. 2018;146:381–96.CrossRef
Metadata
Title
Changes in disease burden and global inequalities in bladder, kidney and prostate cancers from 1990 to 2019: a comparative analysis based on the global burden of disease study 2019
Authors
Qiao Huang
Jun Yang
Guo-Xiong Liu
Hao Zi
Shi-Di Tang
Hai-Chang Jia
Wei Li
Xiao-Feng Xu
Xian-Tao Zeng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18353-9

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue

Study Protocol

A randomized controlled trial of the dissemination of an mHealth intervention for improving health outcomes: the WiseApp for Spanish-speakers living with HIV study protocol

Research

Nonpharmacological intervention therapies for dementia: potential break-even intervention price and savings for selected risk factors in the European healthcare system

Research

Is new tech a pain in the neck? The impact of introducing new technologies in home-care on neck pain: a prospective study

Research

Modifiable risk factors for cancer in the middle East and North Africa: a scoping review

Research

Relationship between 24-h activity behavior and body fat percentage in preschool children: based on compositional data and isotemporal substitution analysis

Research

Association between depressive symptoms and employment type of Korean workers: the Fifth Korean Working Conditions Survey